NCT00079768View on ClinicalTrials.gov

Alemtuzumab to Treat Sporadic Inclusion Body Myositis

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Myositis, Inclusion Body
Interventions
DRUG

Alemtuzumab (Campath)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00079768 - Alemtuzumab to Treat Sporadic Inclusion Body Myositis | Biotech Hunter | Biotech Hunter